Overview

How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Patients with chronic kidney disease and end stage renal disease have greater cardiovascular risk than the general population. Vitamin D analogues have been shown in observational studies to have mortality benefit for these patients. This study is designed to investigate doxercalciferol's effect on the vasculature (i.e. endothelial cell function) as a possible mechanism to explain the mortality benefit.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborator:
Genzyme, a Sanofi Company
Treatments:
1 alpha-hydroxyergocalciferol
Ergocalciferols